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Abstract
Imaging plays a key role in the preclinical evaluation of nanomedicine-based drug delivery
systems and it has provided important insights into their mechanism of action and therapeutic
effect. Its role in supporting the clinical development of nanomedicine products, however, has
been less explored. In this review, we summarize clinical studies in which imaging has provided
valuable information on the pharmacokinetics, biodistribution, and target site accumulation of
nanomedicine-based drug delivery systems. Importantly, these studies provide convincing
evidence on the uptake of nanomedicines in tumors, confirming that the enhanced permeability
and retention (EPR) effect is a real phenomenon in patients, albeit with fairly high levels of inter-
and intraindividual variability. It is gradually becoming clear that imaging is critically important to
help address this high heterogeneity. In support of this notion, a decent correlation between
nanomedicine uptake in tumors and antitumor efficacy has recently been obtained in two
independent studies in patients, exemplifying that image-guided drug delivery can help to pave
the way towards individualized and improved nanomedicine therapies.
Key words: Nanomedicine, Drug delivery, Liposome, PET, SPECT, MRI, Ultrasound,
Nanoparticle, Companion diagnostic, EPR
Introduction
Drug delivery systems based on nanoparticle technologies
have been explored for more than 40 years, being one of the
most active multidisciplinary fields of research to date [1].
Of the several drug delivery platforms available, liposomes,
polymers, and solid inorganic nanoparticles have been the
most widely studied. The rationale behind these drug carrier
systems is to exploit their specific pharmacokinetic and
biodistribution properties to deliver sufficient therapeutic
amounts of the drug cargo to the specific target(s) (the drug
being usually a toxic and/or insoluble small molecule), and
to reduce its side effects due to local controlled release. To
date, several nanomedicine drug delivery systems based on
these concepts have been translated into clinical products,
these include Abraxane®, DaunoXome®, Doxil®/Caelyx®,
Marqibo®, Myocet®, and Onivyde® among others, with
more in clinical trials (9 45 found in ClinicalTrials.gov).
Imaging has played a very important role in the progress
of this field. From a developmental perspective, it allows the
non-invasive measurement of the biodistribution and phar-
macokinetics of these drug delivery systems in animalCorrespondence to: Rafael T. M. de Rosales; e-mail: rafael.torres@kcl.ac.uk
The Author(s), 2018
models of disease, allowing us to select the best candidates
by providing answers to important questions such as BWhere
do they go inside the body?,^ BHow long do they stay?,^
BHow are they cleared?,^ BAre they reaching the target? and
if so, how much?,^ and BIs the drug being released?.^
Several imaging techniques are available to obtain such
information. To gain a deeper understanding of the different
preclinical imaging modalities available—with their intrinsic
advantages and disadvantages—and how they have sup-
ported the preclinical development of drug delivery
systems—we refer the reader to several recent reviews on
this area [2–7].
In the clinical setting, imaging can play an additional role
due to human and disease heterogeneity. It is widely
accepted that human/disease heterogeneity affects the effi-
cacy of all therapies and is particularly detrimental to the
clinical effectiveness and translation of therapeutic
nanomedicines [8–10]. Unlike in animal models of disease,
where most frequently the same genetic strains of mice and
disease cell lines are used to assess the efficacy of drug
delivery systems, in humans, heterogeneity is present
between patients with different diseases, those with the
same disease, and even within different lesions of the same
patient. This heterogeneity has led to nanomedicines being
approved based on their improved safety profile compared to
conventional drugs, rather than improvements in therapeutic
efficacy [11]. Hence, to overcome this problem, imaging
methods that allow us to predict at the patient-to-patient
level the efficacy of drug delivery systems, as well other
therapeutics, could play important roles in the future [9].
The objective of this review is to analyze the progress and
future prospects in the area of imaging drug delivery in
humans. Our aim is twofold: first, we want to provide a
descriptive analysis to date on how different clinical imaging
techniques have played an important role in providing proof-
of-concept data to support the development of drug delivery
systems into clinical products. Second, we aim at highlight-
ing how recent studies are shining new light into the inter-
and intra-patient heterogeneity problem and how imaging
can be used to predict drug delivery/therapeutic efficacy.
Where possible, we have also tried to highlight findings
from all of these studies that, in our opinion, deserve further
attention.
To identify clinical studies in the field of image-guided
drug delivery, we searched PubMed in January 2018, using
combinations of the following terms: drug delivery, imaging,
liposome, MRI, nanomedicine, nanoparticle, PET,
radiolabeled, scintigraphy, SPECT, and ultrasound. Results
were then restricted to clinical trials and articles were
manually screened for relevance (Table 1). Studies in which
imaging, most frequently x-ray computed tomography (CT)
and 2-deoxy-2-[18F]fluoro-D-glucose (FDG) positron emis-
sion tomography (PET), was used solely for monitoring
response to treatment were not included. With the focus
being on nanomedicine drug delivery systems, studies of
labeled small molecules and antibodies were not considered.
For a brief overview of antibody-based theranostics, we refer
the reader to the excellent review by Moek et al. [32]. The
results of our search showed that liposome technologies are
the most studied drug delivery system in humans. For
reviews on image-guided drug delivery focused more
specifically on clinical applications of liposomes in combi-
nation with imaging, we refer the reader to recently
published reviews by Petersen et al. [33] and Lamichhane
et al. [34]. Our search results also highlighted that the
majority of the clinical studies of imaging-guided drug
delivery to date have been performed using nuclear imaging
modalities, principally planar gamma scintigraphy with only
a minority using single-photon emission computed tomog-
raphy (SPECT) or PET. This was followed by fewer studies
using ultrasound (US) and magnetic resonance imaging
(MRI). A brief description of each imaging technique is
provided in each section, and the reader will find an
excellent overview and comparison of the various imaging
techniques in the introduction to molecular imaging by
James and Gambhir [35]. All results have been organized in
two levels, imaging technique and disease.
Clinical Studies Using Gamma
Scintigraphy and Single-Photon
Emission Computed Tomography
Imaging
Gamma scintigraphy and single-photon emission computed
tomography (SPECT) imaging rely on gamma-emitting
radioisotopes, most commonly technetium-99m (99mTc,
t1/2 = 6.0 h, γ = 140 keV), indium-111 (
111In,
t1/2 = 2.8 day, γ = 171 keV, 245 keV), iodine-123 (
123I,
t1/2 = 13.2 h, γ = 159 keV), or iodine-131 (
131I,
t1/2 = 8.0 day, γ = 364 keV) in the clinic. The signal is
captured by a gamma camera, equipped with collimators to
localize the origin of the signal. Conventional scintigraphy
provides two-dimensional (2D) images. In SPECT imaging,
the gamma camera is rotated around the patient to obtain
multiple 2D projections which can then be reconstructed into
a three-dimensional (3D) image. Current clinical SPECT
scanners provide a spatial resolution of 8–10 mm, a
temporal resolution of a few minutes and a sensitivity of
10−10 to 10−11 mol/l of radiotracer [35].
Oncology
Most of the studies involved imaging liposomes radiolabeled
with Tc-99m or In-111 to evaluate drug delivery to tumor
sites. Following preclinical studies showing accumulation of
liposomes in tumors, early clinical studies were aimed at
establishing both the safety of the liposomes and their use as
imaging agents for tumor detection and staging [36–39]. For
example, Lopez-Berestein et al. [12] administered Tc-99m-
labeled liposomes to seven cancer patients. It was unclear at
the time whether early-generation liposomes selectively
684 Man F. et al.: Imaging Nanomedicine-Based Drug Delivery: Clinical Studies
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accumulated at tumor sites, and therefore liposomes were
primarily seen as a means to reduce the toxicity of their
payload or to target macrophages. The study revealed the
accumulation of liposomes in macrophage-rich tissues such
as the lungs, liver, and spleen, but did not mention any
accumulation at the tumor sites. It is, however, unlikely that
this could have been observed, considering that the four out
of seven patients had various forms of leukemia, and one of
those with a solid tumor was in complete remission. The
value of this study lies more in its demonstration of the
safety and relative ease of using radiolabeled liposomes in
humans. The safety of the technique was confirmed in the
first clinical study using In-111-labeled liposomes, con-
ducted by Turner et al. [13, 14]. Although the study was
unblinded, accumulation of liposomes was observed at
known tumor sites in 22 out of 24 patients, and revealed
unsuspected tumors in 3 patients, demonstrating the utility of
radiolabeled liposomes for tumor detection. Furthermore, a
high variability of liposomal uptake in tumors was noted,
possibly the first observation of enhanced permeability and
retention (EPR) effect heterogeneity in humans. The same
group later published what remains by far the largest clinical
trial of radiolabeled nanomedicines, in terms of number of
patients imaged [15]. Even on this larger scale, In-111-
labeled liposomes were safe to use, and the authors reported
70–80 % sensitivity and 90 % specificity for non-cerebral
tumor detection. Scintigraphic images of patients with
Kaposi’s sarcoma and head and neck cancer (HNC) showed
accumulation of radioactivity at the tumor sites [16]. The
authors concluded to the usefulness of In-111-labeled
liposomes as a diagnostic tool and of liposomes in general
as drug delivery vehicles. Later, Khalifa et al. reported low
uptake but excellent tumor delineation in seven out of eight
patients with high-grade glioma using In-111-labeled lipo-
somes [17].
Two particularly noteworthy studies are those performed
by Stewart, Harrington, and colleagues [18, 19]. By then,
liposome technology had witnessed the development and
clinical approval of so-called stealth, i.e., polyethylene
glycol (PEG)-coated, or PEGylated, liposomes with in-
creased circulation times [40]. The first study aimed at
establishing the biodistribution pattern of stealth liposomes
in 17 patients with solid tumors. The extended circulation
time compared to earlier-generation liposomes [41] was
confirmed by scintigraphic imaging. Tumor accumulation of
the radiolabeled liposomes was evident, in some cases for up
to 10 days after administration, with eightfold variations in
uptake between tumors (Table 2). In the second, more
detailed study, 15 patients with locally advanced breast
cancer, lung cancer, cervix cancer, or squamous cell HNC,
or high-grade glioma, were administered In-111-labeled
PEGylated liposomes, with the aim of obtaining precise
information on the pharmacokinetics of these liposomes.
One of the observations made was that of the daily urinary
excretion of a small percentage of the injected In-111,
presumably caused by the slow degradation of the liposomes
in the tissues. This preliminary observation deserves further
investigation. Indeed, beyond measuring liposomal uptake in
the tumor, radiolabeling liposomes could provide a means of
quantifying the amount of drug released from the liposomes.
In the present case, In-111 urinary excretion might be used
as a surrogate marker of drug release from the liposomal
formulation. Scintigraphy showed a long circulation time of
the liposomes and accumulation mostly in the liver and
spleen. This was accompanied by a high stability of the
liposomes that remained in circulation up to 4 days post-
administration. Because this slow clearance from the blood led
to high background signal, accumulation of the In-111-labeled
liposomes in the tumors was not observed in the first 48 h;
however, the tumors were eventually visualized in 15 of the 17
patients studied. One of the main findings from this trial was
that liposomal accumulation in the tumors could be seen for up
to a week after administration. This was demonstrated in the
striking scintigraphic image of a patient with Kaposi’s
sarcoma, illustrating the EPR effect in humans (Fig. 1).
The second lesson was a remarkably large variability of
liposome uptake observed in the tumors, even after
accounting for tumor size. In contrast, uptake in the main
organs (liver, spleen, lungs, kidneys) was rather uniform
between different patients. Although no data were available
to explain this heterogeneity, variability in tumor vascular-
ization and local inflammation were proposed as plausible
explanations, based on preclinical and other clinical studies.
The use of radiolabeled liposomes to predict drug uptake in
patients, in other terms patient stratification, was proposed
by the authors as a way to improve response rates in phase II
clinical studies.
A common feature of the studies described above is that
the liposomes contained no other cargo than the radiotracer.
The first clinical studies of radiolabeled liposomes contain-
ing a therapeutic drug were published in 1999 and 2000 by
Koukourakis et al. [20, 21]. These pilot studies aimed at
evaluating the combination of liposomal doxorubicin
(Caelyx®) with radiotherapy. In the first study, nine patients
with non-small cell lung cancer (NSCLC) and seven patients
with HNC were administered Caelyx® radiolabeled with Tc-
99m and imaged by planar gamma scintigraphy. Accumu-
lation of the liposomes in the tumor sites was observed 2 h
after administration, with tumor-to-blood ratio increasing
after 10 h. In the NSCLC patients, liposomal uptake in the
tumors correlated with the degree of tumor micro-vascular-
ization, showing the presence of the EPR effect. The second
study describes the same experiment in seven patients
presenting locally advanced sarcomas [21] (Fig. 2). The
apparent absence of liposomal drug-related toxicity and the
high response rate (4 complete responses out of 7 patients)
were considered encouraging, despite the low number of
subjects and the absence of a control group. Although no
measurement of doxorubicin levels by either imaging or
biopsy was described, scintigraphy showed accumulation of
Tc-99m at tumor sites previously determined by CT or bone
scans, on average 2.8-fold more than in neighboring normal
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tissue. This again demonstrates the increased uptake of
liposomes in tumors in humans. Finally, another study
described liposomal mifamurtide (Mepact®) radiolabeled
with Tc-99m and administered to four cancer patients for
pharmacokinetic analysis, showing accumulation in lung
metastases in two patients [22].
More recently, Giovinazzo et al. [23] investigated an
indirect approach to imaging liposomal drug delivery,
using Tc-99m sulfur colloid (TSC, Technecoll®) to
inform on the distribution of PEGylated liposomal
doxorubicin (Doxil®). TSC and other Tc-99m-labeled
colloids are clinically approved and routinely used for
Fig. 1. Whole-body gamma camera images over 7 days of a patient with Kaposi’s sarcoma administered In-111-labeled
liposomes. Areas of liposome uptake in the left foot and leg, right arm, and face corresponded with typical Kaposi’s sarcoma
lesions. Prolonged retention of the radiolabel is seen despite significant clearance of circulating liposomes, as demonstrated by
disappearance of the cardiac blood pool image. Adapted with permission from the American Association for Cancer Research:
Harrington et al. [19].
Table 2.. EPR heterogeneity: variability of radiolabeled liposome uptake in tumors. Adapted with permission from the American Association for Cancer
Research: Harrington et al. [19]
Patient Tumor Stage Whole body scan SPECT Total % injected dosea % ID/kgb
1 SCC bronchus T4N0M0 Positive Positive 1.7 12.5
2 SCC bronchus T4N0M0 Positive Positive 1.6 25.4
3 Breast (ductal) T4N2M1 Negative Negative
4 SCCHN T3N2M0 Positive Positive 3.5 46.8
5 Breast (ductal) T4N1M0 Positive Positive 0.3 2.7
6 Breast (ductal) T4N2M1 Positive Positive 1.5 3.9
7 Breast (ductal) T3N2M0 Positive Positive 1.7 9.5
8 SCCHN T4N0M0 Positive Positive 0.7 24.2
9 SCCHN T3N1M0 Positive Positive 1.0 32.0
10 SCC cervix FIGO IIIB Negative Positive NA NA
11 Breast (ductal) T4N2M0 Positive Positive 1.4 5.2
12 SCC bronchus T2N0M1 Negative Negative
13 SCCHN T3N2M0 Positive Positive 0.6 9.0
14 SCCHN T3N0M0 Positive Positive 1.6 53.0
15 SCC bronchus T3N0M1 Positive Positive 2.6 16.7
16 Glioma (AA) Inoperable Negative Positive NA NA
17 Glioma (GBM) Inoperable Negative Positive NA NA
aTumor uptake determined from ROI on 72-h whole-body scan
bPercentage injected dose/kg calculated from estimated tumor volume
SCC, squamous cell cancer; AA, anaplastic astrocytoma (grade III); GBM, glioblastoma multiforme (grade IV); NA, not assessable (tumor uptake was only
measurable from whole-body scans)
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lymphoscintigraphy and staging of cancers [42]. Since
the uptake of PEGylated liposomes is at least in part
mediated by the mononuclear phagocyte system (MPS),
the hypothesis was that the biodistribution of TSC,
which is also cleared through the MPS, would mirror
that of Doxil®. Thus, TSC uptake might be used to
predict the uptake of Doxil® and thereby inform on the
potential efficacy and/or toxicity of this drug, in
particular the risk of developing palmar-plantar
erythrodysesthesia (PPE). Ten patients with epithelial
ovarian cancer were administered TSC, 1 week before
commencing treatment with liposomal doxorubicin. Im-
aging of the spleen, liver, and hands was done by
scintigraphy and SPECT/CT. Levels of TSC in the hands
were highly variable from one patient to another and did
not correlate with blood TSC levels, suggesting variabil-
ity in MPS activity. After finding a positive correlation
between blood levels of TSC and encapsulated doxoru-
bicin, the authors derived a formula to estimate doxoru-
bicin levels in the hands based on TSC measures only.
This estimated value positively correlated with clinical
grades of PPE severity. The main advantage of this
indirect approach is that it is based on a clinically
approved product and could potentially be used as a
general predictor of uptake for nanomedicines that are
cleared through the MPS. On the other hand, it would
still require initial correlation studies to be undertaken
for each nanomedicine, whereas radiolabeling of the
therapeutic nanomedicine directly and specifically in-
forms on the uptake of the drug.
Infection and Inflammation
In an interesting departure from cancer studies, Dams
et al. [24] evaluated the use of 99mTc-labeled PEGylated
liposomes for the detection of infection and inflamma-
tion, as an alternative to the clinical standards repre-
sented by radiolabeled immunoglobulin G (IgG) and
white blood cells. Here, each patient acted as their own
control, being first administered the liposomes and 24 h
later 111In-labeled IgG. Several interesting findings arose
from this study. From a diagnosis perspective, there was
excellent concordance between the results from the scans
with Tc-99m-labeled liposomes and In-111-labeled IgG,
with discordance in only 1 out of 35 patients. The
calculated specificity was identical for both methods, and
the sensitivity was higher with the liposomes. The
liposomes also allowed better delineation of the foci of
accumulation than the IgG in some patients, presumably
Fig. 2. Scintigraphic planar images from four patients with sarcoma administered 99mTc-labeled liposomal doxorubicin
(Caelyx®). a Clockwise from top left: fibrosarcoma of the iliac region, b angiosarcoma of the maxillary andrum, c Ewing
sarcoma of the femur, d Kaposi sarcoma of the palmar area. Adapted with permission from Koukourakis et al. [21].
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because of the lower rate of reverse diffusion of the
liposomes into the blood pool. It should be noted that
the suspected foci were predominantly musculoskeletal
and the radiolabeled liposomes failed to detect the single
case of endocarditis in the study, highlighting a limita-
tion of this approach. As expected, the PEGylated
liposomes showed a long circulation time, with signal
in the blood pool still visible 24 h after administration.
Although the concordance study required the use of a
shorter-lived isotope for the first scan to allow a second
scan as quickly as possible, one might consider the use
of a longer-lived isotope in future studies. This would
allow scanning the patient later, potentially improving
the signal-to-background ratio and thereby facilitating
diagnosis. Later scans may also allow monitoring the
response to treatment. Alternatively, modifications of the
physico-chemical properties of the liposomes might allow
faster clearance from the circulation for more rapid
increases in target-to-background ratios, resulting in
earlier diagnosis. The authors considered radiolabeled
liposomes as a diagnostics tool for detecting infectious or
inflammatory foci. In view of the good performance of
the Tc-99m-labeled PEG liposomes in detecting such
foci, it is clear that radiolabeled liposomes could also be
used as theranostic agents by loading them with
antibiotics or anti-inflammatory drugs. This is particu-
larly true for antibiotics because sub-optimal drug
concentrations at the site of infection can lead to the
appearance of bacterial resistance. Radiolabeled lipo-
somes could help estimate the amount of antibiotic
reaching the infectious foci and allow rapid adjustments
of the therapeutic schedule.
Respiratory Diseases
An example of the aforementioned approach is given in a
study by Weers et al. [25], using a Tc-99m-labeled
liposomal formulation of the aminoglycoside amikacin,
administered through a nebulizer. In this case, using
aerosolized liposomes was intended to provide a slow-
release formulation, reducing dosing frequency, to increase
drug penetration through the bacterial biofilm and to reduce
systemic exposure to the drug. The study was performed in
three healthy subjects and showed that nearly 40 % of the
deposited liposome dose was still present in the lungs 48 h
after administration, indicating longer retention compared to
non-encapsulated drugs. It also clearly showed the
mucociliary escalator in action, with a large fraction of the
deposited dose ending up in the stomach after being cleared
upwards from the airways and swallowed. Although this
radiolabeling approach could potentially have been useful
for larger clinical trials, development of this liposomal
antibiotic (Arikace™) appears to have halted in phase III.
An earlier study of radiolabeled nebulized liposomes had
also shown longer retention of the liposome-encapsulated
tracer [26]. Bhavna et al. [27] compared the distribution of
two Tc-99m-labeled, inhaled formulations of salbutamol (a
long-acting β2 agonist used in asthma and chronic obstruc-
tive pulmonary disease management) with different particle
sizes. The hypothesis was that a reduced particle size would
lead to improved drug delivery by increasing deposition in
the peripheral lung alveoli and reducing uptake by alveolar
macrophages. Although the latter aspect was not described
in the study, scintigraphic images reveal deeper penetration
of the smaller-sized formulation (average particle size
60 nm) compared to the commercial formulation with a
particle size of around 10 μm, as expected for inhaled
particles [43]. Despite intense research efforts in
nanomedicines for drug delivery to the lungs [44], very
few clinical trials appear to have made use of the
possibilities offered by non-invasive imaging techniques.
Clinical Studies Using PET Imaging
The most commonly used positron-emitting radionuclides in
clinical studies are fluorine-18 (F-18, t1/2 = 110 min),
rubidium-82 (Rb-82, t1/2 = 1.3 min), carbon-11 (C-11,
t1/2 = 20.3 min), gallium-68 (Ga-68, t1/2 = 67.8 min),
copper-64 (Cu-64, t1/2 = 12.7 h), and zirconium-89 (Zr-89,
t1/2 = 3.27 day). Positrons emitted from PET radioisotopes
travel up to a short distance (positron range, up to a few mm)
before encountering an electron, at which point an annihi-
lation event produces two 511-keV gamma rays at a near
180° angle. This pair of coincident gamma photons is
detected by the PET camera, in which detectors are arranged
in several static rings, providing 3D images. The coinci-
dence detection allows to dispense with physical collimators
used in SPECT/planar scintigraphy, thereby increasing the
sensitivity of PET scanners by several orders of magnitude
over SPECT scanners, in the range of 10−11 to 10−12 mol/l of
radiotracer, as well as the temporal resolution [35]. The lack
of collimators also results in signals that are more easily
quantifiable than those from gamma-emitting isotopes, and a
maximum spatial resolution of approximately 5 mm. Despite
these advantages, only two recent clinical studies of
nanomedicines using PET have had results published as of
April 2018, both in the field of oncology.
In the context of a clinical trial (NCT01304797) of MM-
302, a formulation of PEGylated liposomal doxorubicin
targeted against human epidermal growth factor receptor 2
(HER2), Lee et al. [28] selected 19 patients with metastatic
breast cancer for an imaging study using MM-302
radiolabeled with Cu-64. Current clinically approved formu-
lations of PEGylated liposomal doxorubicin (Doxil®/
Caelyx®, Myocet®) do not possess targeting moieties and
rely solely in the EPR effect. MM-302 is targeted towards
HER-2 with the objective of increasing delivery of doxoru-
bicin in HER2-overexpressing cells rather than in macro-
phages, as observed in a preclinical study [45].
The authors sought to determine whether the amount of
drug reaching the metastases would correlate with
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therapeutic efficacy. Treatment with MM-302 was given
along with trastuzumab (a clinically approved anti-HER2
monoclonal antibody). The chelating and loading agent 4-
DEAP-ATSC [46] was used to radiolabel MM-302 with Cu-
64, with a target dose of 400 MBq per patient. The
maximum Cu-64 activity remaining in the patients would
be 108 MBq after 24 h and 29 MBq after 48 h, potentially
sufficient for PET imaging at this time point. Results from
PET imaging (Fig. 3) showed that [64Cu]MM-302 remained
in the circulation for over 24 h, and thereafter accumulated
mostly in the liver and spleen, in good agreement with
preclinical data.
The authors state that free Cu-64 was not detectable in the
patients selected for more detailed analysis. This is not
surprising, because free Cu-64 has high affinity for liver and
spleen tissues and rapidly accumulates in these organs [47].
Therefore, assessing the stability of the Cu-64 radiolabeling
of MM-302 based on PET images is not straightforward.
Based on preclinical data showing that the biodistribution of
MM-302 could be affected by treatment with cyclophospha-
mide, the patients selected for the imaging study were taken
both from a group receiving MM-302 and trastuzumab and
from a group receiving cyclophosphamide in addition.
However, no differences in drug uptake were observed
between these two groups, leading the patients to be
analyzed as a single group for the rest of the study. There
were several important results from the study. The first is the
large heterogeneity in drug uptake not only between subjects
but also between lesions within subjects. This high
variability of the EPR effect is particularly important from
a therapeutic point of view, since metastases exposed to
insufficient drug concentrations could serve as starting
points for further dissemination of cancer cells, potentially
negating the initial benefits of the treatment. This led the
authors to stratify the patients according to the amount of
nanomedicine present in the lesion with the lowest uptake.
Although the study was underpowered to show a correlation
between MM-302 uptake and progression-free survival, an
encouraging trend was observed that would warrant the
enrollment of additional patients. A second lesson was the
good agreement between clinical and preclinical data, both
in overall nanomedicine distribution and in drug concentra-
tions in the tumors. This should strengthen the case for
clinical trials when imaging-based preclinical data are
encouraging. Furthermore, the authors found no correlation
between drug concentrations at the tumors and either drug
concentrations in the blood or tumor size. This means that
blood sampling will not be predictive of efficacy and
highlights the added value of quantitative whole-body
imaging techniques. A limitation of this study may para-
doxically reside in the use of Cu-64 as an imaging agent.
PET imaging has also been used by several groups [48–50],
to show that the maximal tumor uptake of PEGylated
liposomes in preclinical models occurs within 24–48 h
post-administration, but imaging at later time points (e.g.,
72 h) improves signal-to-background ratio. In practice, the
half-life of Cu-64 limits the imaging window to approxi-
mately 48 h post-administration and even this duration
Fig. 3. Representative PET and fused PET/CT images of [64Cu]-MM-302 in lesions at different anatomic locations. The regions
of interest used to measure tumor deposition of [64Cu]-MM-302 are shown in blue or turquoise outlines. Adapted with
permission from the American Association for Cancer Research: Lee et al. [28].
690 Man F. et al.: Imaging Nanomedicine-Based Drug Delivery: Clinical Studies
requires high starting amounts of radioactivity. The use of
longer-lived PET isotopes, such as Zr-89 (t1/2 = 3.27 day) or
Mn-52 (t1/2 = 5.59 day), should overcome this barrier.
The other clinical study of a PET-radiolabeled nanomedicine
was conducted by Phillips et al. [29], using fluorescent
nanoparticles conjugated to iodine-124 (I-124, t1/2 = 4.18 day),
for optical and PET imaging. The nanoparticles were also
conjugated to an integrin-targeting peptide and engineered to
promote renal clearance, and were therefore expected to have a
distinct biodistribution pattern compared to liposomal
nanomedicines. Indeed, the authors observed rapid clearance
of the nanoparticles with most of the activity eliminated within
72 h and no accumulation in the liver and spleen. This is an
interesting feature compared to liposomal nanomedicines,
where liver and spleen accumulation complicates the visualiza-
tion of nearby tumors. Although the study focused mainly on
the safety and stability of the nanoparticles, accumulation of the
nanoparticles was observed at tumor sites in some patients, with
increasing target-to-background ratios over time but already
observable within 4 h of administration. This favorable
pharmacokinetic profile may enable faster clinical decisions.
On the other hand, the nanoparticles were observed to
accumulate in the renal cortices of a patient known to have
chemotherapy-induced kidney inflammation, potentially com-
plicating the differentiation between tumor areas and inflam-
matory lesions. There would be no reason to expect off-tumor
inflammation in preclinical models of cancer, and therefore such
a chance observation could only be made in a clinical study.
This shows the value of incorporating whole-body imaging at
the earliest opportunity in clinical studies of nanomedicines.
Furthermore, the combination with an optical probe is an
excellent choice for clinical applications of multimodal imag-
ing, allowing tumor localization by PET to be followed by
fluorescence-guided surgery for improved tumor resection,
ultimately resulting in improved patient outcomes.
Clinical Studies Using Magnetic
Resonance Imaging
In magnetic resonance imaging, the subject is placed in a
powerful magnetic field, which will align magnetically
active nuclei (most commonly hydrogen from water mole-
cules) either parallel or anti-parallel to the magnetic field.
The small difference in the number of nuclei aligning in each
direction gives rise to the magnetic resonance imaging
(MRI) signal. A pulsed radiofrequency can then be used to
temporarily disturb the alignments of the nuclei, and the
relaxation time back to the original position is measured.
This relaxation time is dependent on the environment of the
nuclei, for example, hydrogen nuclei in a fat-rich environ-
ment, or with short distance of an iron oxide nanoparticle,
have shorter relaxation times than those in an aqueous
environment. It is important to note that when using contrast
agents in MRI, the measured signal arises not directly from
the imaging agent but from the changes in magnetic
properties the agent induces in its local environment. MRI
has a much lower sensitivity than nuclear imaging tech-
niques and requires imaging agent concentrations in the
range of 10−3 to 10−5 mol/l, which can have pharmacological
effects. Although MRI avoids the use of ionizing radiation,
the inherent presence of MR-active nuclei means that at least
two imaging sessions are necessary when imaging drug
delivery: one before the administration of the MR-detectable
agent, and one at a suitable time after administration. In
addition, accurate quantification of the signal derived from
contrast agents in MRI, particularly those based on
superparamagnetic iron oxide materials, is difficult. On the
other hand, the spatial resolution of clinical MRI is
approximately 1 mm, providing far more detailed images
than PET or SPECT [35].
In a recent study, Ramanathan et al. [30] described an
interesting approach to image-guided drug delivery. The aim
was to use the tumor deposition of Ferumoxytol, a carboxy-
dextran-coated superparamagnetic iron oxide nanoparticle with
long circulation time and affinity for macrophages [51], as a
surrogate marker for tumor deposition of nal-IRI (MM-398,
Onivyde®), a nanoliposomal formulation of the topoisomerase
I inhibitor irinotecan. Both Ferumoxytol and nal-IRI are
clinically approved products. The driving idea was that the
amount of nanomedicine reaching the tumor would depend
more on the vascular permeability at the tumor site and the
average particle size than on the specific composition of the
nanomedicine, so that iron nanoparticles and liposomes with
otherwise comparable pharmacokinetics would reach the tumor
in similar amounts. This study was performed in 13 patients
with solid tumors, of which 9 were also assessed for treatment
response by CT. Ferumoxytol uptake was quantified by T2*
imaging (Fig. 4), and irinotecan levels were measured from
patient biopsies. There was no statistically significant correla-
tion between Ferumoxytol uptake and irinotecan levels.
In a similar two-class approach to that used by Lee et al.
[28] in the PET study of MM-302 described above, the
authors classified lesions according to their Ferumoxytol
uptake (below or above the median of uptake in all lesions).
Using this approach, lesions with above-median
Ferumoxytol uptake showed significantly improved changes
in size after nal-IRI treatment over those with below-median
uptake. Another major finding of this study was the high
variability of Ferumoxytol between patients and between
lesions in a given patient, echoing the high variability of the
EPR effect reported for Tc-99m- and Cu-64-labeled
PEGylated liposomes [19, 28]. This MRI-based study takes
a Bcompanion diagnostic^ approach akin to that used in the
TSC/Doxil® combination study by Giovinazzo et al. [23].
Since the uptake of one drug is used as an indirect reflection
of the uptake of a second therapeutic drug, there is an
inherent possibility of pharmacokinetic/biodistribution dif-
ferences between the two drugs. Correlations must therefore
be established in preliminary studies for each envisaged
reporter/drug combination before the pair can be used in the
clinic. However, the use of clinically approved imaging
agents could easily be integrated into existing treatment
Man F. et al.: Imaging Nanomedicine-Based Drug Delivery: Clinical Studies 691
protocols by not having to go through the same regulatory
hurdles as theranostic agents, which could be considered as
new drugs and therefore require full regulatory approval.
Two other clinical trials (NCT02022644 andNCT03086616)
of nal-IRI that include image-guided drug delivery are planned.
Convection-enhanced delivery (CED) of nal-IRI to the brain of
pediatric and adult patients with glioma will be followed in real
time by MRI, using co-administered gadolinium-based contrast
agents.
Clinical Studies Using Ultrasound
Imaging
Ultrasound imaging relies on sending sound waves through
the body and recording the reflected waves to produce a
high-resolution 2D image. This is done with a hand-held
probe, making it a widely available and very cost-effective
technique, but is mostly limited to soft tissue imaging [35].
There is a large body of preclinical work on focused
ultrasound (FUS)-mediated drug delivery, especially using
thermosensitive liposomes, with the imaging aspect typically
performed by ultrasound or MRI. For further information on
this topic, the reader is directed to recent and extensive
reviews [52–54]. We have found only one report related to
ultrasound-guided drug delivery in humans. Lyon et al. [31]
recently described the protocol of an ongoing (as of April
2018) clinical trial of ThermoDox®, a thermosensitive
liposomal formulation of doxorubicin with FDA approval
for investigational use. By using low-intensity FUS to
visualize liver tumors and induce mild hyperthermia, the
aim is to selectively increase the concentration of doxoru-
bicin at the tumor sites. Doxorubicin levels will be measured
by high-performance liquid chromatography in biopsied
tumor tissues before and after application of FUS. Only the
first few patients are to undergo tumor biopsy before FUS, to
establish an average tumor concentration of doxorubicin
prior to FUS application. The authors describe this as a way
of reducing the number of invasive procedures performed on
the patients. However, considering the variability of liposo-
mal uptake in tumors highlighted in the MM-302 study [28],
we caution that this approach might yield misleading results.
It would be preferable, especially for a pilot study, to
determine pre-FUS doxorubicin concentration in as many
patients as possible to adequately quantify the effect of FUS
on liposomal drug release. Other imaging modalities such as
[18F]FDG PET-CT and dynamic-contrast enhanced (DCE)-
MRI are included in the study, but aimed at establishing
baseline tumor imaging and potential response to treatment
rather than evaluating drug delivery. Results from this study
have yet to be published; however, it will be of considerable
interest to see whether a non-invasive and non-ionizing
method such as FUS can be used to increase doxorubicin
concentrations above therapeutic threshold specifically in
cancerous tissue to minimize the effect on healthy tissues.
Conclusions and Perspectives
Imaging has been successfully used in humans to study the
biodistribution and pharmacokinetics of nanomedicine-based
drug delivery systems, demonstrating its value for this
purpose. Significant findings from these studies include
solid proof that (1) EPR as the most common uptake
mechanism for nanomedicines in tumors/inflamed tissues is
a real phenomenon in patients and (2) the EPR effect is
highly heterogeneous, between diseases, patients, and even
lesions within a single patient. This heterogeneity may
underlie the fact that nanomedicines have not always shown
superiority in clinical therapeutic activity over conventional
drugs, despite an improved safety profile [11]. Indeed, an
absence of therapeutic effect does not imply absence of
Fig. 4. a Representative pseudocolored relaxometric R2* maps derived from patient images before and after administration of
iron oxide nanoparticle (Ferumoxytol®, FMX). Approximate lesion locations are indicated by white lines in the image before
FMX dosing. b Extrapolated FMX concentrations in individual patients 24 h after administration. Adapted with permission from
the American Association for Cancer Research: Ramanathan et al. [30].
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nanomedicine accumulation in tumors. This is particularly
relevant for metastatic cancers, as nanomedicine accumula-
tion only at certain tumor sites may not be sufficient for an
overall survival benefit to the patient. Moreover, recent
clinical studies have demonstrated a clear correlation
between nanomedicine accumulation levels in target tissues
(e.g., tumors) and therapeutic effect, supporting the use of
imaging to identify patients that will respond to the
treatment. An important concept that arises from these
studies is the development of companion diagnostics, based
on clinically approved imaging agents that correlate with
nanomedicine biodistribution. Another conclusion from this
review is that most of the studies to date have been in the
oncology field, leaving further opportunities for image-
guided drug delivery studies beyond this area, particularly
in the fields of infection and respiratory medicine.
A general limitation of the nanomedicine-imaging ap-
proaches described in this review is that they are in practice
indirect methods. Indeed, the imaging agent is most frequently
attached to the carrier rather than to the drug, whereas clinically
the most relevant information is the localization of the drug
itself, which may differ from that of the carrier after release.
This would generally require chemical modification of the
drug. Furthermore, it is extremely challenging to differentiate
between nanocarrier-bound and released drug by non-invasive
imaging. This may be possible by optical imaging, especially
for intrinsically fluorescent drugs, in vitro and possibly at the
preclinical level, but not in humans [55]. An option is co-
loading liposomes with a drug and a magnetic resonance (MR)
contrast agent, as the relaxivity of the encapsulated and non-
encapsulated MR contrast agent will differ [56], but this
method suffers from the inherent limitations of MRI discussed
above (sensitivity, challenging whole-body detection/quantifi-
cation). Furthermore, it will not inform on drug distribution
after release and at later times. Nuclear imaging modalities may
be helpful in this context, for example, by loading radiolabeled
drugs into nanocarriers; however, the half-lives of the
radioisotopes most amenable to radiolabeling of small mole-
cules (e.g., C-11 and F-18) are too short to match the biological
half-lives of nanomedicines. In this context, a recent preclinical
study demonstrated the concept of radiolabeling both the
liposome carrier and the encapsulated drug with PET radionu-
clides [57]. Another possibility is to use multi-isotope SPECT
and image both the carrier and the drug orthogonally; however,
this is only possible when using radionuclides with different
gamma emission energies (e.g., Tc-99m and In-111). Longer
imaging windows are attainable by using metal-chelating drugs
and radiometals such as Zr-89 [48]; however, this raises
another issue, which is the stability of the free radionuclide/
label. Even the longer-lived and covalently bound radioiodine
(I-124, I-125, I-131) labels are susceptible to deiodination
in vivo. As mentioned previously, the accumulation of the free
radiolabel in specific anatomical locations (e.g., the thyroid for
radioiodine, bones for Zr-89, or pancreas for Mn-52 [58]) may
inform on the extent of drug release from the carrier. Even this
requires the assumption that the rate of release of the radiolabel
from the drug is similar to the drug release from the carrier and
will not inform about drug localization.
Despite all these issues, it is clear that among the different
imaging techniques available, nuclear medicine techniques
have been the most used to date, most likely due to their whole-
body capabilities and excellent quantification properties.
Importantly, their high sensitivity also allows imaging with
sub-therapeutic nanomedicine doses in the microdose range
(1 % of the therapeutic dose), which facilitates clinical
translation. MRI and US circumvent the use of radioactivity
and provide higher spatio-temporal resolution, at the expense
of lower sensitivity and higher imaging agent doses. In
addition, performing quantitative whole-body imaging with
MRI and US is a more complex process than with nuclear
imaging. For these reasons, it is likely that future clinical
studies in this area will include nuclear imaging as the main
quantitative method to assess nanomedicine/drug concentra-
tion in vivo. The recent study by Lee et al. [28] using
[64Cu]MM-302 is an excellent example of the way clinical
image-guided drug delivery studies should be conducted
nowadays, particularly for its approach to patient stratification.
We believe that incorporating imaging into studies of
nanomedicine drug delivery will undoubtedly provide valuable
additional information that standard techniques such as blood
sampling and biopsy cannot provide. This will greatly benefit
the clinical development of new nanomedicines and help
achieve the full potential of those already developed.
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